Healthcare - Medical - Instruments & Supplies - NYSE - CA
$ 19.68
0.562 %
$ 6.93 B
Market Cap
-18.92
P/E
CASH FLOW STATEMENT
-17 M
OPERATING CASH FLOW
-2.11 B
INVESTING CASH FLOW
2.08 B
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bausch + Lomb Corporation
| Net Income | -248 M |
| Depreciation & Amortization | 382 M |
| Capital Expenditures | -181 M |
| Stock-Based Compensation | 74 M |
| Change in Working Capital | -287 M |
| Others | -75 M |
| Free Cash Flow | -198 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (248.0) | 15.0 | 193.0 | (17.0) | 303.0 | 719.0 |
| Depreciation & Amortization | 382.0 | 379.0 | 415.0 | 442.0 | 469.0 | 495.0 |
| Deferred Income Tax | (10.0) | (90.0) | 116.0 | 97.0 | (39.0) | (444.0) |
| Stock Based Compensation | 74.0 | 62.0 | 62.0 | 50.0 | 50.0 | 43.0 |
| Other Operating Activities | 72.0 | (2.0) | 59.0 | 9.0 | 56.0 | 28.0 |
| Change in Working Capital | (287.0) | (19.0) | 28.0 | (59.0) | (40.0) | (78.0) |
| Cash From Operations | (17.0) | 345.0 | 873.0 | 522.0 | 799.0 | 763.0 |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (181.0) | (175.0) | (209.0) | (259.0) | (180.0) | (101.0) |
| Other Items | (1 928.0) | (40.0) | (5.0) | 3.0 | (6.0) | 27.0 |
| Cash From Investing Activities | (2 109.0) | (215.0) | (214.0) | (256.0) | (186.0) | (74.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (10.0) | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 2 115.0 | 2 458.0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37.0) | (2 377.0) | (712.0) | (232.0) | (606.0) | (665.0) |
| Cash From Financing Activities | 2 078.0 | 81.0 | (712.0) | (232.0) | (606.0) | (665.0) |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (46.0) | 203.0 | (61.0) | 46.0 | 4.0 | 16.0 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (198.0) | 170.0 | 664.0 | 263.0 | 619.0 | 662.0 |